Literature DB >> 33513836

Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner.

Angelo Iacobino1, Giovanni Piccaro2, Manuela Pardini1, Lanfranco Fattorini1, Federico Giannoni1.   

Abstract

Previous studies on Escherichia coli demonstrated that sub-minimum inhibitory concentration (MIC) of fluoroquinolones induced the SOS response, increasing drug tolerance. We characterized the transcriptional response to moxifloxacin in Mycobacterium tuberculosis. Reference strain H37Rv was treated with moxifloxacin and gene expression studied by qRT-PCR. Five SOS regulon genes, recA, lexA, dnaE2, Rv3074 and Rv3776, were induced in a dose- and time-dependent manner. A range of moxifloxacin concentrations induced recA, with a peak observed at 2 × MIC (0.25 μg/mL) after 16 h. Another seven SOS responses and three DNA repair genes were significantly induced by moxifloxacin. Induction of recA by moxifloxacin was higher in log-phase than in early- and stationary-phase cells, and absent in dormant bacilli. Furthermore, in an H37Rv fluoroquinolone-resistant mutant carrying the D94G mutation in the gyrA gene, the SOS response was induced at drug concentrations higher than the mutant MIC value. The 2 × MIC of moxifloxacin determined no significant changes in gene expression in a panel of 32 genes, except for up-regulation of the relK toxin and of Rv3290c and Rv2517c, two persistence-related genes. Overall, our data show that activation of the SOS response by moxifloxacin, a likely link to increased mutation rate and persister formation, is time, dose, physiological state and, possibly, MIC dependent.

Entities:  

Keywords:  DNA repair; Mycobacterium tuberculosis; SOS response; fluoroquinolone; moxifloxacin

Year:  2021        PMID: 33513836     DOI: 10.3390/microorganisms9020255

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  6 in total

1.  Structure-Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors.

Authors:  Andreas Beuchel; Dina Robaa; Dereje A Negatu; Abdeldjalil Madani; Nadine Alvarez; Matthew D Zimmerman; Adrian Richter; Lea Mann; Sophie Hoenke; René Csuk; Thomas Dick; Peter Imming
Journal:  ACS Med Chem Lett       Date:  2022-02-28       Impact factor: 4.345

2.  Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.

Authors:  Preshendren Govender; Rudolf Müller; Kawaljit Singh; Virsinha Reddy; Charles J Eyermann; Stephen Fienberg; Sandeep R Ghorpade; Lizbé Koekemoer; Alissa Myrick; Dirk Schnappinger; Curtis Engelhart; Jaclynn Meshanni; Jo Ann W Byl; Neil Osheroff; Vinayak Singh; Kelly Chibale; Gregory S Basarab
Journal:  J Med Chem       Date:  2022-05-02       Impact factor: 8.039

3.  Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.

Authors:  Dereje Abate Negatu; Andreas Beuchel; Abdeldjalil Madani; Nadine Alvarez; Chao Chen; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Benoît Laleu; Martin Gengenbacher; Véronique Dartois; Peter Imming; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

4.  Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.

Authors:  Gregory S Basarab; Sandeep Ghorpade; Liezl Gibhard; Rudolf Mueller; Mathew Njoroge; Nashied Peton; Preshendren Govender; Lisa M Massoudi; Gregory Thomas Robertson; Anne J Lenaerts; Helena Ingrid Boshoff; Douglas Joerss; Tanya Parish; Thomas F Durand-Reville; Manos Perros; Vinayak Singh; Kelly Chibale
Journal:  Antimicrob Agents Chemother       Date:  2022-03-10       Impact factor: 5.938

5.  Dissecting the RecA-(In)dependent Response to Mitomycin C in Mycobacterium tuberculosis Using Transcriptional Profiling and Proteomics Analyses.

Authors:  Anna Brzostek; Przemysław Płociński; Alina Minias; Aneta Ciszewska; Filip Gąsior; Jakub Pawełczyk; Bożena Dziadek; Marcin Słomka; Jarosław Dziadek
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

6.  Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

Authors:  Kirsten E Knoll; Zander Lindeque; Adetomiwa A Adeniji; Carel B Oosthuizen; Namrita Lall; Du Toit Loots
Journal:  Microorganisms       Date:  2021-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.